Patterns of curative treatment for non-small cell lung cancer in New South Wales, Australia

被引:2
|
作者
Batumalai, Vikneswary [1 ,2 ]
Descallar, Joseph [1 ]
Gabriel, Gabriel [1 ]
Delaney, Geoff P. [1 ,3 ]
Oar, Andrew [4 ]
Barton, Michael B. [1 ,3 ]
Vinod, Shalini K. [1 ,3 ]
机构
[1] Univ New South Wales, Collaborat Canc Outcomes Res & Evaluat, Ingham Inst Appl Med Res, South Western Clin Sch, Sydney, NSW, Australia
[2] GenesisCare, Bldg 1&11,41-43 Bourke Rd, Alexandria, NSW 2015, Australia
[3] South Western Sydney Local Hlth Dist, Dept Radiat Oncol, Sydney, NSW, Australia
[4] Gold Coast Univ Hosp, Icon Canc Ctr, Gold Coast, Australia
关键词
curative; non-small cell lung cancer; practice patterns; radiotherapy; surgery; RADIOTHERAPY; CARE; COMORBIDITY; DISPARITIES; SURGERY; IMPACT; AGE;
D O I
10.1111/ajco.13811
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction There is a lack of large population-based studies examining patterns of curative treatment for non-small cell lung cancer (NSCLC) in Australia. This study aimed to evaluate the utilization of curative treatment for NCSLC at a population level and identify factors associated with its use in New South Wales (NSW), Australia. Methods Patients diagnosed with localized or locoregional NSCLC between 2009 and 2014 were identified from the NSW Central Cancer Registry. Curative treatment was defined as surgery or radiotherapy with a 45 Gy minimum dose. Univariate and multivariable analyses were performed to investigate factors associated with the receipt of curative treatment. A Cox proportional-hazards regression model was used to analyze the factors associated with 2-year overall survival (OS). Results Of the 5722 patients diagnosed with NSCLC in the study period, 3355 (59%) patients received curative treatment and 2367 (41%) patients did not receive curative treatment. The receipt of curative treatment was significantly associated with younger patients, female gender, localized disease, and Charlson Comorbidity Index (CCI) = 0. The use of curative treatment increased significantly over time from 2009 (55%) to 2014 (63%) and varied significantly from 24% to 70% between local health districts (LHDs) of residence. Younger age, female gender, localized disease, CCI = 0, and overseas country of birth were significantly associated with 2-year OS. The 2-year OS significantly improved from 70% in 2009 to 77% in 2014 for patients who received curative treatment. Conclusion The use of curative treatment for patients with potentially curable NSCLC was low at 59%. However, the use of curative treatment and survival have increased over time. Significant variation was noted in the use of curative treatment between LHDs.
引用
收藏
页码:E149 / E159
页数:11
相关论文
共 50 条
  • [31] TIME TO TREATMENT IN PATIENTS WITH STAGE III NON-SMALL CELL LUNG CANCER
    Wang, Li
    Correa, Candace R.
    Hayman, James A.
    Zhao, Lujun
    Cease, Kemp
    Brenner, Dean
    Arenberg, Doug
    Curtis, Jeffery
    Kalemkerian, Gregory P.
    Kong, Feng-Ming
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 74 (03): : 790 - 795
  • [32] Surgical treatment of oligometastatic non-small cell lung cancer
    Pfannschmidt, Joachim
    Dienemann, Hendrik
    LUNG CANCER, 2010, 69 (03) : 251 - 258
  • [33] Treatment Toxicity in Elderly Patients With Advanced Non-Small Cell Lung Cancer
    Kale, Minal S.
    Mhango, Grace
    Gomez, Jorge E.
    Sigel, Keith
    Smith, Cardinale B.
    Bonomi, Marcelo
    Wisnivesky, Juan P.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2017, 40 (05): : 470 - 476
  • [34] Induction chemoradiotherapy followed by surgery for locally advanced non-small cell lung cancer
    Kusumoto, Sojiro
    Hirose, Takashi
    Fukayama, Motoko
    Kataoka, Daisuke
    Hamada, Kenji
    Sugiyama, Tomohide
    Shirai, Takao
    Yamaoka, Toshimitsu
    Okuda, Kentaro
    Ohnishi, Tsukasa
    Ohmori, Tohru
    Kadokura, Mitsutaka
    Adachi, Mitsuru
    ONCOLOGY REPORTS, 2009, 22 (05) : 1157 - 1162
  • [35] Therapeutic options for regionally advanced non-small cell lung cancer
    Buccheri, G
    Ferrigno, D
    LUNG CANCER, 1996, 14 (2-3) : 281 - 300
  • [36] Surgery for non-small cell lung cancer - new trends
    Waller, DA
    LUNG CANCER, 2001, 34 : S133 - S136
  • [37] Neoadjuvant treatment in non-small cell lung cancer: New perspectives with the incorporation of immunotherapy
    Aguado, Carlos
    Chara, Luis
    Antonanzas, Monica
    Matilla Gonzalez, Jose Maria
    Jimenez, Unai
    Hernanz, Raul
    Mielgo-Rubio, Xabier
    Trujillo-Reyes, Juan Carlos
    Counago, Felipe
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2022, 13 (05): : 314 - 322
  • [38] Preoperative chemotherapy for non-small cell lung cancer
    Depierre, A
    Westeel, V
    Jacoulet, P
    CANCER TREATMENT REVIEWS, 2001, 27 (02) : 119 - 127
  • [39] Treatment patterns and outcomes change in early-stage non-small cell lung cancer in octogenarians and older: a SEER database analysis
    Bei, Yanping
    Chen, Xue
    Raturi, Vijay Parshuram
    Liu, Kaitai
    Ye, Shuang
    Xu, Quan
    Lu, Miaozhen
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2021, 33 (01) : 147 - 156
  • [40] Postoperative radiotherapy for non-small cell lung cancer
    Burdett, Sarah
    Rydzewska, Larysa
    Tierney, Jayne
    Fisher, David
    Parmar, Mahesh K. B.
    Arriagada, Rodrigo
    Pignon, Jean Pierre
    Le Pechoux, Cecile
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (10):